• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ProMIS Neurosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/12/26 6:45:26 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PMN alert in real time by email
    PROMIS NEUROSCIENCES INC._May 12, 2026
    0001374339false00013743392026-05-122026-05-12

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 12, 2026

    PROMIS NEUROSCIENCES INC.

    (Exact name of registrant as specified in its charter)

    ​

    Canada

      ​ ​ ​

    001-41429

      ​ ​ ​

    98-0647155

    (State or other jurisdiction
    of incorporation)

     

    (Commission
    File Number)

     

    (IRS Employer
    Identification No.)

    ​

    ​

    Suite 200, 1920 Yonge Street,
    Toronto, Ontario

      ​ ​ ​

     

      ​ ​ ​

    M4S 3E2

    (Address of principal executive
    offices)

     

     

     

    (Zip Code)

    ​

    Registrant’s telephone number, including area code: (416) 847-6898

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of Each Class

      ​ ​ ​

    Trading Symbol(s)

      ​ ​ ​

    Name of Each Exchange on Which Registered

    Common Shares, no par value per share

    ​

    PMN

    The Nasdaq Capital Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

    Emerging growth company  ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    Item 2.02 Results of Operations and Financial Condition

    On May 12, 2026, ProMIS Neurosciences Inc. (the "Company") issued a press release, which is available on its website (www.promisneurosciences.com under “Investors/Financial Results”), reporting its financial condition and financial results as of and for the quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this report and is incorporated by reference into this Item 2.02.

    ​

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    ​

    ​

    ​

    Exhibit No.

      ​ ​ ​

    Description

    99.1

    ​

    Press Release, dated May 12, 2026

    104

    ​

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    ​

    ​

    ​

    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    ​

    PROMIS NEUROSCIENCES INC.

    ​

    ​

    ​

    Date: May 12, 2026

    By:

    /s/ Neil Warma

    ​

    ​

    Name: Neil Warma

    ​

    ​

    Title: Chief Executive Officer

    ​

    ​

    ​

    Get the next $PMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProMIS Neurosciences to Participate in Upcoming Conferences in June

    CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings. Conference details below:Jefferies Global Healthcare Conference, June 2-4, 2026Location: New York, NYPresentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ETWebcast link: Click here.Virtual Alzheimer's R&D Day, organized by Wolfe Research, June 4, 2026Presentation: Thursday, June 4, 2026, from 8:30 a.m. to 9:00 a.

    5/28/26 10:13:28 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

    Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through 2027, including completion of the ongoing Phase 1b clinical trial in Alzheimer's disease (AD).PRECISE-AD Phase 1b trial is fully enrolled and progressing on schedule, with the blinded 6-month interim analysis anticipated in early Q3 2026 and 12-month top-line data anticipated in early 2027. The planned interim analysis is expected to include a qualitative assessment of aggregated safety data, including amyloid-related imaging abnormalities (ARIA) incidence, as well as key biomarker trends acros

    5/12/26 6:30:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

    PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 continues to demonstrate a favorable safety profile, with no treatment-related serious adverse events reported to date Cambridge, Massachusetts,, March 25, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinso

    3/25/26 8:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    SEC Filings

    View All

    SEC Form S-8 filed by ProMIS Neurosciences Inc.

    S-8 - ProMIS Neurosciences Inc. (0001374339) (Filer)

    5/29/26 4:15:40 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)

    5/20/26 4:30:26 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by ProMIS Neurosciences Inc.

    SCHEDULE 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)

    5/15/26 8:55:38 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirwin Patrick D. bought $45,320 worth of shares (4,000 units at $11.33) (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    4/23/26 9:25:00 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Williams Eugene bought $48,800 worth of shares (2,000 units at $24.40), increasing direct ownership by 19% to 12,397 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    3/6/26 7:28:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Williams Eugene bought $92,420 worth of shares (4,000 units at $23.11), increasing direct ownership by 63% to 10,397 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    3/4/26 6:08:32 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Wyman William W

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    5/22/26 4:35:46 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Williams Eugene

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    5/22/26 4:35:15 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Warma Neil K

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    5/22/26 4:34:42 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Leadership Updates

    Live Leadership Updates

    View All

    ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

    Appointment reinforces ProMIS Neurosciences' strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer's program, PMN310 Cambridge, Massachusetts, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Slanix Paul Alex, Pharm.D., President and Portfolio Manager for Ally Bridge Group's Public Equity strategy, has joined the Company's Board of Directors. Dr. Alex has a highly distinguished Wall Street career spanning multiple leadership positions at public market

    10/22/25 7:30:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

    CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. "We continue to make significant progress as we are nearing completion of the Phase 1a single ascending dose clinical trial of PMN310 in Alzheimer's disease and remain on track to report top-

    5/14/24 4:01:00 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

    CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update. "I am pleased to have taken the helm of ProMIS at the beginning of 2024 and am proud of the meaningful progress the team has made to date as ProMIS made the transition to a clinical deve

    4/1/24 4:15:00 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

    SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/14/24 4:56:13 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ProMIS Neurosciences Inc.

    SC 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/14/24 3:36:04 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

    SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/6/24 4:15:57 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Financials

    Live finance-specific insights

    View All

    ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

    Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through 2027, including completion of the ongoing Phase 1b clinical trial in Alzheimer's disease (AD).PRECISE-AD Phase 1b trial is fully enrolled and progressing on schedule, with the blinded 6-month interim analysis anticipated in early Q3 2026 and 12-month top-line data anticipated in early 2027. The planned interim analysis is expected to include a qualitative assessment of aggregated safety data, including amyloid-related imaging abnormalities (ARIA) incidence, as well as key biomarker trends acros

    5/12/26 6:30:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

    PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 continues to demonstrate a favorable safety profile, with no treatment-related serious adverse events reported to date Cambridge, Massachusetts,, March 25, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinso

    3/25/26 8:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care